|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C2orf49 |
Gene summary for C2ORF49 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C2orf49 | Gene ID | 79074 |
| Gene name | chromosome 2 open reading frame 49 | |
| Gene Alias | asw | |
| Cytomap | 2q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0007275 | UniProtAcc | C9J4K0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79074 | C2orf49 | LZE4T | Human | Esophagus | ESCC | 1.93e-09 | 2.26e-01 | 0.0811 |
| 79074 | C2orf49 | LZE7T | Human | Esophagus | ESCC | 3.66e-03 | 1.67e-01 | 0.0667 |
| 79074 | C2orf49 | LZE8T | Human | Esophagus | ESCC | 3.80e-02 | 3.91e-02 | 0.067 |
| 79074 | C2orf49 | LZE20T | Human | Esophagus | ESCC | 4.65e-02 | 5.98e-02 | 0.0662 |
| 79074 | C2orf49 | LZE24T | Human | Esophagus | ESCC | 2.27e-11 | 2.03e-01 | 0.0596 |
| 79074 | C2orf49 | P1T-E | Human | Esophagus | ESCC | 2.74e-06 | 2.48e-01 | 0.0875 |
| 79074 | C2orf49 | P2T-E | Human | Esophagus | ESCC | 2.79e-19 | 2.18e-01 | 0.1177 |
| 79074 | C2orf49 | P4T-E | Human | Esophagus | ESCC | 2.79e-22 | 4.88e-01 | 0.1323 |
| 79074 | C2orf49 | P5T-E | Human | Esophagus | ESCC | 8.03e-25 | 3.64e-01 | 0.1327 |
| 79074 | C2orf49 | P8T-E | Human | Esophagus | ESCC | 8.63e-15 | 2.11e-01 | 0.0889 |
| 79074 | C2orf49 | P9T-E | Human | Esophagus | ESCC | 1.12e-16 | 3.31e-01 | 0.1131 |
| 79074 | C2orf49 | P10T-E | Human | Esophagus | ESCC | 8.73e-26 | 5.20e-01 | 0.116 |
| 79074 | C2orf49 | P11T-E | Human | Esophagus | ESCC | 1.72e-06 | 2.80e-01 | 0.1426 |
| 79074 | C2orf49 | P12T-E | Human | Esophagus | ESCC | 1.61e-14 | 2.59e-01 | 0.1122 |
| 79074 | C2orf49 | P15T-E | Human | Esophagus | ESCC | 1.46e-24 | 4.57e-01 | 0.1149 |
| 79074 | C2orf49 | P16T-E | Human | Esophagus | ESCC | 8.85e-17 | 2.01e-01 | 0.1153 |
| 79074 | C2orf49 | P17T-E | Human | Esophagus | ESCC | 6.04e-04 | 1.87e-01 | 0.1278 |
| 79074 | C2orf49 | P19T-E | Human | Esophagus | ESCC | 1.18e-03 | 2.93e-01 | 0.1662 |
| 79074 | C2orf49 | P20T-E | Human | Esophagus | ESCC | 1.11e-20 | 3.76e-01 | 0.1124 |
| 79074 | C2orf49 | P21T-E | Human | Esophagus | ESCC | 2.80e-22 | 3.14e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C2orf49 | SNV | Missense_Mutation | novel | c.419N>A | p.Arg140Lys | p.R140K | Q9BVC5 | protein_coding | tolerated(0.11) | benign(0.037) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C2orf49 | SNV | Missense_Mutation | c.176N>G | p.Pro59Arg | p.P59R | Q9BVC5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| C2orf49 | SNV | Missense_Mutation | c.296N>A | p.Arg99Lys | p.R99K | Q9BVC5 | protein_coding | deleterious(0) | probably_damaging(0.986) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| C2orf49 | SNV | Missense_Mutation | rs765886202 | c.214N>G | p.Lys72Glu | p.K72E | Q9BVC5 | protein_coding | deleterious(0.03) | possibly_damaging(0.78) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| C2orf49 | SNV | Missense_Mutation | c.440C>T | p.Ser147Leu | p.S147L | Q9BVC5 | protein_coding | tolerated(0.06) | benign(0.262) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| C2orf49 | SNV | Missense_Mutation | rs368281845 | c.566N>T | p.Ser189Leu | p.S189L | Q9BVC5 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| C2orf49 | SNV | Missense_Mutation | novel | c.635A>G | p.Glu212Gly | p.E212G | Q9BVC5 | protein_coding | deleterious(0.03) | possibly_damaging(0.726) | TCGA-G4-6321-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | SD |
| C2orf49 | SNV | Missense_Mutation | c.440N>T | p.Ser147Leu | p.S147L | Q9BVC5 | protein_coding | tolerated(0.06) | benign(0.262) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| C2orf49 | SNV | Missense_Mutation | rs368281845 | c.566N>T | p.Ser189Leu | p.S189L | Q9BVC5 | protein_coding | tolerated(0.6) | benign(0.003) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| C2orf49 | SNV | Missense_Mutation | novel | c.175N>T | p.Pro59Ser | p.P59S | Q9BVC5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |